Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(3):303–307. doi: 10.1054/bjoc.2000.1566

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP

A Messori 1, M Vaiani 1, S Trippoli 1, L Rigacci 2, M Jerkeman 3, G Longo 2
PMCID: PMC2363752  PMID: 11161392

Abstract

In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P  = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: non-Hodgkin's lymphoma, survival, meta-analysis, chemotherapy

Full Text

The Full Text of this article is available as a PDF (118.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collins R., Yusuf S., Peto R. Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) 1985 Jan 5;290(6461):17–23. doi: 10.1136/bmj.290.6461.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cooper I. A., Wolf M. M., Robertson T. I., Fox R. M., Matthews J. P., Stone J. M., Ding J. C., Dart G., Matthews J., Firkin F. C. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol. 1994 Apr;12(4):769–778. doi: 10.1200/JCO.1994.12.4.769. [DOI] [PubMed] [Google Scholar]
  3. Edmiston C. E., Jr, Josephson A., Pottinger J., Ciacco-Tsivitis M., Palenik C. The numbers game: sample-size determination. Am J Infect Control. 1993 Jun;21(3):151–154. doi: 10.1016/0196-6553(93)90007-q. [DOI] [PubMed] [Google Scholar]
  4. Ferrandina G., Scambia G., Bardelli F., Benedetti Panici P., Mancuso S., Messori A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer. 1997;76(5):661–666. doi: 10.1038/bjc.1997.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fine H. A., Dear K. B., Loeffler J. S., Black P. M., Canellos G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993 Apr 15;71(8):2585–2597. doi: 10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  6. Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Jr, Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002–1006. doi: 10.1056/NEJM199304083281404. [DOI] [PubMed] [Google Scholar]
  7. Gianni A. M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997 May 1;336(18):1290–1297. doi: 10.1056/NEJM199705013361804. [DOI] [PubMed] [Google Scholar]
  8. Goldie J. H., Coldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982 Mar;66(3):439–449. [PubMed] [Google Scholar]
  9. Gordon L. I., Harrington D., Andersen J., Colgan J., Glick J., Neiman R., Mann R., Resnick G. D., Barcos M., Gottlieb A. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992 Nov 5;327(19):1342–1349. doi: 10.1056/NEJM199211053271903. [DOI] [PubMed] [Google Scholar]
  10. Guglielmi C., Gherlinzoni F., Amadori S., Mazza P., Mantovani L., Lauria F., Martelli M., Zinzani P. L., Greco V., Poletti G. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Haematologica. 1989 Nov-Dec;74(6):563–569. [PubMed] [Google Scholar]
  11. Jeng G. T., Scott J. R., Burmeister L. F. A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage. JAMA. 1995 Sep 13;274(10):830–836. [PubMed] [Google Scholar]
  12. Jerkeman M., Anderson H., Cavallin-Ståhl E., Dictor M., Hagberg H., Johnson A., Kaasa S., Kvaløy S., Sundström C., Akerman M. CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol. 1999 Sep;10(9):1079–1086. doi: 10.1023/a:1008392528248. [DOI] [PubMed] [Google Scholar]
  13. Linch D. C., Vaughan Hudson B., Hancock B. W., Hoskin P. J., Cunningham D. C., Newland A. C., Milligan D. W., Stevenson P. A., Wood J. K., MacLennan K. A. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. Br J Cancer. 1996 Jul;74(2):318–322. doi: 10.1038/bjc.1996.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Martelli M., De Sanctis V., Avvisati G., Mandelli F. Current guidelines for the management of aggressive non-Hodgkin's lymphoma. Drugs. 1997 Jun;53(6):957–972. doi: 10.2165/00003495-199753060-00005. [DOI] [PubMed] [Google Scholar]
  15. Mazza P., Zinzani P. L., Martelli M., Fiacchini M., Bocchia M., Pileri S., Falini B., Martelli M. F., Amadori S., Papa G. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk Lymphoma. 1995 Feb;16(5-6):457–463. doi: 10.3109/10428199509054434. [DOI] [PubMed] [Google Scholar]
  16. Messori A., Bosi A., Bacci S., Laszlo D., Trippoli S., Locatelli F., Van Lint M. T., Di Bartolomeo P., Amici A. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant. 1999 Mar;23(5):489–495. doi: 10.1038/sj.bmt.1701600. [DOI] [PubMed] [Google Scholar]
  17. Messori A., Brignola C., Trallori G., Rampazzo R., Bardazzi G., Belloli C., d'Albasio G., De Simone G., Martini N. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol. 1994 May;89(5):692–698. [PubMed] [Google Scholar]
  18. Messori A., Rampazzo R. Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Methods Programs Biomed. 1993 Aug;40(4):261–267. doi: 10.1016/0169-2607(93)90011-9. [DOI] [PubMed] [Google Scholar]
  19. Messori A., Trippoli S., Becagli P., Zaccara G. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci. Pharmacoeconomics. 1999 Aug;16(2):153–163. doi: 10.2165/00019053-199916020-00004. [DOI] [PubMed] [Google Scholar]
  20. Montserrat E., García-Conde J., Viñolas N., López-Guillermo A., Hernández-Nieto L., Zubizarreta A., Maldonado J., Alcalá A., Faura M. V., Llorente A. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol. 1996 Nov;57(5):377–383. doi: 10.1111/j.1600-0609.1996.tb01396.x. [DOI] [PubMed] [Google Scholar]
  21. Oxman A. D., Clarke M. J., Stewart L. A. From science to practice. Meta-analyses using individual patient data are needed. JAMA. 1995 Sep 13;274(10):845–846. doi: 10.1001/jama.274.10.845. [DOI] [PubMed] [Google Scholar]
  22. Steinberg K. K., Smith S. J., Stroup D. F., Olkin I., Lee N. C., Williamson G. D., Thacker S. B. Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. Am J Epidemiol. 1997 May 15;145(10):917–925. doi: 10.1093/oxfordjournals.aje.a009051. [DOI] [PubMed] [Google Scholar]
  23. Stewart L. A., Parmar M. K. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993 Feb 13;341(8842):418–422. doi: 10.1016/0140-6736(93)93004-k. [DOI] [PubMed] [Google Scholar]
  24. Trallori G., Messori A., Scuffi C., Bardazzi G., Silvano R., d'Albasio G., Pacini F. 5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: a meta- and economic analysis. J Clin Gastroenterol. 1995 Apr;20(3):257–259. doi: 10.1097/00004836-199504000-00022. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES